BR112017010188A2 - análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer - Google Patents

análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer

Info

Publication number
BR112017010188A2
BR112017010188A2 BR112017010188-2A BR112017010188A BR112017010188A2 BR 112017010188 A2 BR112017010188 A2 BR 112017010188A2 BR 112017010188 A BR112017010188 A BR 112017010188A BR 112017010188 A2 BR112017010188 A2 BR 112017010188A2
Authority
BR
Brazil
Prior art keywords
cancer
drug carriers
targeting drug
phospholipid ether
ether analogues
Prior art date
Application number
BR112017010188-2A
Other languages
English (en)
Other versions
BR112017010188B1 (pt
Inventor
P. Weichert Jamey
Pinchuk Anatoly
Kozak Kevin
Longino Marc
Grudzinski Joseph
Titz Benjamin
Pak Chorom
Stehle Nathan
Original Assignee
Cellectar Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences, Inc. filed Critical Cellectar Biosciences, Inc.
Publication of BR112017010188A2 publication Critical patent/BR112017010188A2/pt
Publication of BR112017010188B1 publication Critical patent/BR112017010188B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção é dirigida a compostos terapêuticos capazes de alvejar células cancerígenas e células-tronco cancerígenas. a presente invenção é ainda dirigida a composições compreendendo estes compostos terapêuticos e métodos de tratamento de câncer compreendendo a administração destes compostos terapêuticos. o composto terapêutico compreendendo a fórmula a-b-d em que: a é pelo menos um composto de fórmula (i).
BR112017010188-2A 2014-11-17 2015-11-06 Análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer BR112017010188B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080436P 2014-11-17 2014-11-17
US62/080,436 2014-11-17
PCT/US2015/059382 WO2016081203A2 (en) 2014-11-17 2015-11-06 Phospholipid ether analogs as cancer-targeting drug vehicles

Publications (2)

Publication Number Publication Date
BR112017010188A2 true BR112017010188A2 (pt) 2018-02-14
BR112017010188B1 BR112017010188B1 (pt) 2023-03-28

Family

ID=55960741

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010188-2A BR112017010188B1 (pt) 2014-11-17 2015-11-06 Análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer

Country Status (18)

Country Link
US (4) US9345718B1 (pt)
EP (2) EP3229810B1 (pt)
JP (1) JP6832861B2 (pt)
KR (1) KR102500181B1 (pt)
CN (2) CN116655690A (pt)
AU (1) AU2015350400B2 (pt)
BR (1) BR112017010188B1 (pt)
CA (1) CA2968145C (pt)
DK (2) DK3750545T3 (pt)
EA (1) EA037519B1 (pt)
ES (1) ES2811367T3 (pt)
IL (1) IL252102B (pt)
MX (1) MX2017006382A (pt)
PT (1) PT3229810T (pt)
SG (1) SG11201703979QA (pt)
SI (2) SI3229810T1 (pt)
TW (1) TWI576341B (pt)
WO (1) WO2016081203A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3229810B1 (en) * 2014-11-17 2020-07-22 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
CA2998528A1 (en) 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2016349577B2 (en) 2015-11-06 2023-10-26 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
WO2018022571A1 (en) 2016-07-25 2018-02-01 Wisconsin Alumni Research Foundation Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
CA3031750A1 (en) * 2016-07-25 2018-02-01 Wisconsin Alumni Research Foundation Radioactive phospholipid metal chelates for cancer imaging and therapy
CN110612119A (zh) * 2017-02-07 2019-12-24 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
JP2021512147A (ja) 2018-01-22 2021-05-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Ｃａｒ ｔ細胞の使用方法
JP2021512622A (ja) * 2018-02-06 2021-05-20 シアトル チルドレンズ ホスピタル ディー／ビー／エー シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ−ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
JP7402172B2 (ja) * 2018-04-10 2023-12-20 セレクター・バイオサイエンシズ・インコーポレイテッド リン脂質－フラバグリン複合体およびそれを標的癌治療に使用する方法
EP3937975A4 (en) * 2019-03-13 2023-06-21 Seattle Children's Hospital (DBA Seattle Children's Research Institute) SODIUM FLUORESCEIN AS A REVERSAL AGENT FOR ANTIFLUORESCEIN CAR-T CELLS AND FLUORESCEIN PHOSPHOLIPIDE ETHERS OR FLUORESCEIN PHOSPHOLIPIDE ETHERS OR PROFLUORESCEIN PHOSPHOLIPIDE ETHERS
TWI705813B (zh) 2019-05-24 2020-10-01 國立交通大學 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途
EP3992276A4 (en) * 2019-06-27 2022-09-07 Showa Denko Materials Co., Ltd. CELL SCAFFOLD MATERIAL, SUPPORT AND METHOD FOR CELL CULTURE
AU2020346898A1 (en) 2019-09-12 2022-04-07 Cellectar Biosciences, Inc. Phospholipid ether conjugates as cancer-targeting drug vehicles
BR112022006739B1 (pt) * 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965391A (en) * 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DE4408011C1 (de) 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
AU3000800A (en) * 1999-02-18 2000-09-04 Supergen, Inc. Phosphocholine linked prodrug derivatives
IL131887A0 (en) * 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US7632644B2 (en) 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
WO2005084716A2 (en) 2004-03-02 2005-09-15 Cellectar, Llc Phospholipid analogs for diagnosis and treatment of cancer
KR20070054630A (ko) 2004-07-08 2007-05-29 셀렉타, 엘엘씨 방사성-표지된 인지질 에테르 유사체를 이용한 가상대장내시경검사법
EP1833514A2 (en) 2004-12-20 2007-09-19 Cellectar, Llc Phospholipid ether analogs for detecting and treating cancer
UA99434C2 (ru) 2005-12-19 2012-08-27 Аетерна Центаріс Гмбх Применение производных алкилфосфолипидов со сниженной цитотоксичностью
WO2008150439A1 (en) * 2007-06-01 2008-12-11 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
US7893286B2 (en) 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
ES2535217T3 (es) * 2007-11-28 2015-05-07 Celator Pharmaceuticals, Inc. Sistema mejorado de administración de taxano
US20100284931A1 (en) * 2009-05-11 2010-11-11 Pinchuk Anatoly Fluorescent phospholipid ether compounds, compositions, and methods of use
US7811548B1 (en) 2009-05-11 2010-10-12 Cellectar, Inc. Fluorescent phospholipid ether compounds and compositions
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
JP5702366B2 (ja) 2009-05-11 2015-04-15 セレクター，インコーポレイティド 蛍光リン脂質エーテル化合物、組成物、及びその使用
US20100286510A1 (en) * 2009-05-11 2010-11-11 Pinchuk Anatoly Use of fluorescent phospholipid ether compounds in biopsies
WO2010144788A2 (en) 2009-06-12 2010-12-16 Cellectar, Inc. Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
WO2011031919A2 (en) 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
WO2013016658A1 (en) 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof
EP3229810B1 (en) * 2014-11-17 2020-07-22 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
FI3888658T3 (fi) 2015-11-25 2024-03-22 Effector Therapeutics Inc eIF4A:ta inhiboivia yhdisteitä ja niihin liittyviä menetelmiä
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
JP7402172B2 (ja) 2018-04-10 2023-12-20 セレクター・バイオサイエンシズ・インコーポレイテッド リン脂質－フラバグリン複合体およびそれを標的癌治療に使用する方法

Also Published As

Publication number Publication date
DK3229810T3 (da) 2020-08-17
MX2017006382A (es) 2018-04-10
NZ731669A (en) 2021-02-26
US20160228564A1 (en) 2016-08-11
SI3229810T1 (sl) 2021-01-29
SG11201703979QA (en) 2017-06-29
US20180333498A1 (en) 2018-11-22
WO2016081203A2 (en) 2016-05-26
EA201791094A1 (ru) 2017-09-29
KR20170106304A (ko) 2017-09-20
PT3229810T (pt) 2020-08-27
IL252102B (en) 2021-10-31
BR112017010188B1 (pt) 2023-03-28
IL252102A0 (en) 2017-08-31
EP3750545A1 (en) 2020-12-16
TWI576341B (zh) 2017-04-01
US11439709B2 (en) 2022-09-13
WO2016081203A3 (en) 2016-08-18
US20160136290A1 (en) 2016-05-19
US9480754B2 (en) 2016-11-01
US9345718B1 (en) 2016-05-24
EA037519B1 (ru) 2021-04-07
EP3750545B1 (en) 2024-03-27
AU2015350400A1 (en) 2017-05-25
DK3750545T3 (da) 2024-04-22
CN116655690A (zh) 2023-08-29
TW201619145A (zh) 2016-06-01
CN107708702A (zh) 2018-02-16
US20160136190A1 (en) 2016-05-19
ES2811367T3 (es) 2021-03-11
AU2015350400B2 (en) 2020-11-05
EP3229810A2 (en) 2017-10-18
EP3229810B1 (en) 2020-07-22
EP3229810A4 (en) 2018-07-25
CA2968145C (en) 2023-06-27
CA2968145A1 (en) 2016-05-26
JP2017535608A (ja) 2017-11-30
KR102500181B1 (ko) 2023-02-14
US9925269B2 (en) 2018-03-27
SI3750545T1 (sl) 2024-06-28
JP6832861B2 (ja) 2021-02-24

Similar Documents

Publication Publication Date Title
BR112017010188A2 (pt) análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
BR112016023558A2 (pt) compostos úteis como imunomoduladores
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112017027147A2 (pt) agente estimulante de restauração/crescimento de cabelo
BR112016014180A2 (pt) reguladores de nrf2
NZ749217A (en) Androgen receptor modulator and uses thereof
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
PE20151448A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150571A (es) Compuestos y composiciones terapéuticos
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CL2015002027A1 (es) Compuestos quimicos
GT201500247A (es) Imidazopiridazinas sustituidas
CO7101239A2 (es) Composiciones derivadas de la quitosana
UY35922A (es) Derivados de sulfonamidas tricíclicas
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX2016004967A (es) Tratamiento para cancer pancreatico.
SV2017005520A (es) Derivados de tetrahidropiranil benzamida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: CELLECTAR BIOSCIENCES, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2015, OBSERVADAS AS CONDICOES LEGAIS